Systemic Lupus Erythematosus - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Systemic Lupus Erythematosus - Pipeline Review, H2 2013 market report to its offering
Systemic Lupus Erythematosus - Pipeline Review, H2 2013


, 'Systemic Lupus Erythematosus - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Systemic Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus. Systemic Lupus Erythematosus - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Systemic Lupus Erythematosus.
- A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Systemic Lupus Erythematosus pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Amgen Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Genentech, Inc.
MedImmune LLC
Biotest AG
Novo Nordisk A/S
Pfizer Inc.
Rigel Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
UCB Group
Hadasit Medical Research Services & Development Ltd
Merck KGaA
Hollis-Eden Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Karo Bio
Portola Pharmaceuticals, Inc.
Dynavax Technologies Corporation
Hansa Medical AB
Shenzhen Beike Biotechnology Co., Ltd.
Immupharma Plc
Neovacs SA
Hutchison MediPharma Limited
Argos Therapeutics, Inc.
MacroGenics, Inc.
Kineta, Inc.
Biotica Technology Ltd
Xencor, Inc.
Cornerstone Therapeutics Inc.
CBio Limited
Anthera Pharmaceuticals Inc.
SuppreMol GmbH
NasVax Ltd.
Amplimmune, Inc.
Lycera Corp.
America Stem Cell, Inc.

To view the table of contents for this market research report please visit